Literature DB >> 3487332

Long-term follow-up of serum-interferon and its acid-stability in a group of homosexual men.

E Buimovici-Klein, M Lange, R J Klein, M H Grieco, L Z Cooper.   

Abstract

For a period of over two years 99 volunteer healthy homosexual men were examined periodically for the presence of interferon (IFN) in their serum. Thirty-nine subjects had either undetectable IFN levels in serum or IFN was detected only once in three to five samples tested. In another 45 subjects low IFN levels were detected throughout the study period. None of these subjects had or developed any disease symptoms. In the remaining 15 subjects high serum IFN levels were detected at their enrollment or during the study period. All these subjects started to manifest clinical symptoms compatible with AIDS. In six subjects the mean time elapsed between the first detection of serum IFN and disease symptoms was 6.5 months. In all subjects but one, the IFN was of type alpha. The acid-stability of serum IFN alpha decreased with time, and when its decrease was abrupt it was associated with a more rapid evolution of AIDS. Sera containing acid-labile IFN alpha can induce IFN alpha synthesis in normal lymphocyte cultures (LC), but do not influence IFN gamma synthesis in LC stimulated with phytohemagglutinin. LC stimulated with viral antigens in the presence of serum with acid-labile IFN alpha synthesized IFN with an increased sensitivity for acid treatment. The results confirm the prognostic value of serum IFN alpha in the development of AIDS, and suggest that the transition to acid-lability may be a gradual process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487332     DOI: 10.1089/aid.1.1986.2.99

Source DB:  PubMed          Journal:  AIDS Res        ISSN: 0737-6006


  10 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

Review 2.  A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection.

Authors:  Franck J Barrat; Lishan Su
Journal:  J Exp Med       Date:  2019-08-16       Impact factor: 14.307

Review 3.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.

Authors:  LiGuo Zhang; Eric Meissner; JianZhu Chen; LiShan Su
Journal:  Sci China Life Sci       Date:  2010-03-07       Impact factor: 6.038

Review 4.  Plasmacytoid dendritic cells in HIV infection: striking a delicate balance.

Authors:  Patricia Fitzgerald-Bocarsly; Evan S Jacobs
Journal:  J Leukoc Biol       Date:  2010-02-09       Impact factor: 4.962

5.  Cytokine-mediated regulation of monocyte/macrophage cytotoxicity in human immunodeficiency virus-1 infection.

Authors:  S Rossol; G Gianni; R Rossol-Voth; H Gallati; W E Müller; K H Meyer zum Büschenfelde
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

6.  HIV antigen, HIV antibody and serum interferon in a patient with encephalopathy.

Authors:  J Abb; R Zachoval; V Zachoval; F Deinhardt
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

7.  Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice.

Authors:  Guangming Li; Menglan Cheng; Jun-Ichi Nunoya; Liang Cheng; Haitao Guo; Haisheng Yu; Yong-Jun Liu; Lishan Su; Liguo Zhang
Journal:  PLoS Pathog       Date:  2014-07-31       Impact factor: 6.823

Review 8.  Human natural interferon-alpha producing cells.

Authors:  P Fitzgerald-Bocarsly
Journal:  Pharmacol Ther       Date:  1993-10       Impact factor: 12.310

Review 9.  The use of interferon-alpha in virus infections.

Authors:  N B Finter; S Chapman; P Dowd; J M Johnston; V Manna; N Sarantis; N Sheron; G Scott; S Phua; P B Tatum
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

10.  Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile.

Authors:  A M Yee; J P Buyon; Y K Yip
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.